Literature DB >> 30192925

Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients.

Nagalingeswaran Kumarasamy1, Sandeep Prabhu2, Ezhilarasi Chandrasekaran1, Selvamuthu Poongulali1, Amrose Pradeep1, Devaraj Chitra1, Ramasamy Balakrishnan1, Constance A Benson3.   

Abstract

In this first study of generic dolutegravir (DTG)-containing regimens in a low-resource setting, we assessed safety, tolerability, and efficacy within a prospective cohort of 564 patients with at least 6 months of clinical follow-up. We provide support for a large-scale transition to DTG as part of first-line regimens.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; dolutegravir; efficacy; resource-limited setting; safety

Year:  2019        PMID： 30192925      PMCID： PMC7182123          DOI： 10.1093/cid/ciy763

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Usefulness of an observational database to assess antiretroviral treatment trends in India.

Authors:  A J Cecelia; P Christybai; S Anand; K Jayakumar; T Gurunathan; P Vidya; S Solomon; N Kumarasamy
Journal:  Natl Med J India       Date:  2006 Jan-Feb       Impact factor: 0.537

2.  Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.

Authors:  C Hoffmann; T Welz; M Sabranski; M Kolb; E Wolf; H-J Stellbrink; C Wyen
Journal:  HIV Med       Date:  2016-11-10       Impact factor: 3.180

3.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

4.  Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.

Authors:  Sej Todd; P Rafferty; E Walker; M Hunter; W W Dinsmore; C M Donnelly; E J McCarty; S P Quah; C R Emerson
Journal:  Int J STD AIDS       Date:  2017-01-24       Impact factor: 1.359

5.  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Authors:  Kelly E Dooley; Patrick Sayre; Julie Borland; Elizabeth Purdy; Shuguang Chen; Ivy Song; Amanda Peppercorn; Stephanie Everts; Stephen Piscitelli; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

6.  Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Authors:  Qing Ma; Florin Vaida; Jenna Wong; Chelsea A Sanders; Yu-ting Kao; David Croteau; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; Susan Morgello; David M Simpson; Robert K Heaton; Igor Grant; Scott L Letendre
Journal:  J Neurovirol       Date:  2015-09-25       Impact factor: 2.643

7.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Authors:  Francois Raffi; Anita Rachlis; Hans-Jürgen Stellbrink; W David Hardy; Carlo Torti; Chloe Orkin; Mark Bloch; Daniel Podzamczer; Vadim Pokrovsky; Federico Pulido; Steve Almond; David Margolis; Clare Brennan; Sherene Min
Journal:  Lancet       Date:  2013-01-08       Impact factor: 79.321

Review 8.  Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.

Authors:  Christopher E Kandel; Sharon L Walmsley
Journal:  Drug Des Devel Ther       Date:  2015-07-07       Impact factor: 4.162

9.  Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India.

Authors:  Nagalingeswaran Kumarasamy; Sruthi Sundaram; Selvamuthu Poongulali; Chandrasekaran Ezhilarasi; Ambrose Pradeep; Devaraj Chitra
Journal:  J Virus Erad       Date:  2018-01-01

10.  The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.

Authors:  Amy Zheng; Nagalingeswaran Kumarasamy; Mingshu Huang; A David Paltiel; Kenneth H Mayer; Bharat B Rewari; Rochelle P Walensky; Kenneth A Freedberg
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396
  10 in total
  3 in total

1.  Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India.

Authors:  Atul K Patel; Ketan K Patel; Sanjay Pujari; Jagdish K Patel; Ambuj Kumar
Journal:  Indian J Sex Transm Dis AIDS       Date:  2021-05-03

2.  Patterns and prognosis of holding regimens for people living with HIV in Asian countries.

Authors:  Jung Ho Kim; Awachana Jiamsakul; Sasisopin Kiertiburanakul; Bui Vu Huy; Suwimon Khusuwan; Nagalingeswaran Kumarasamy; Oon Tek Ng; Penh Sun Ly; Man-Po Lee; Yu-Jiun Chan; Yasmin Mohamed Gani; Iskandar Azwa; Anchalee Avihingsanon; Tuti Parwati Merati; Sanjay Pujari; Romanee Chaiwarith; Fujie Zhang; Junko Tanuma; Cuong Duy Do; Rossana Ditangco; Evy Yunihastuti; Jeremy Ross; Jun Yong Choi
Journal:  PLoS One       Date:  2022-03-30       Impact factor: 3.240

3.  A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naïve Adult Indian Patients Living with HIV-1.

Authors:  Ameet Dravid; Dnyanesh Morkar; Dwijendra Prasad; John T Ramapuram; Kartik Vikrambhai Patel; K Sunil Naik; Milind Bhrusundi; Milind Kulkarni; Sanjeev Hegde; S Anuradha; Siddabathuni Nageswaramma; Surabhi Madan; Thammisetty Jayaprakash; Vinay Kulkarni
Journal:  Pragmat Obs Res       Date:  2022-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.